BIOVAXYS ANNOUNCES ISSUANCE OF DPX RELATED PATENT FROM THE U.S. PATENT AND TRADEMARK OFFICE
Rhea-AI Summary
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) has been issued U.S. Patent No. 12,042,537 by the USPTO for inducing an antibody immune response using a low dose volume delivery of a B-cell epitope formulated with DPX™. This proprietary lipid-based delivery platform allows for a robust and long-duration immune response. The technology enables delivery of less than 100 µl, packaging 5-50 µL of an antigen.
Potential applications include epitope-based vaccines for chronic hepatitis-B, influenza, and RSV. A previous Phase 1 study of DPX-RSV showed promising results, with 93% of participants maintaining antigen-specific immune responses after nine months. This patent issuance strengthens BioVaxys' position for further development and potential partnerships in epitope-based vaccine development.
Positive
- Issuance of U.S. Patent No. 12,042,537 for low dose volume delivery of B-cell epitope with DPX™
- Patent already allowed in Japan and pending in the European Union
- Potential applications in vaccines for chronic hepatitis-B, influenza, and RSV
- Previous Phase 1 study showed 93% of participants maintained immune responses after 9 months
- 100% of older adults maintained immune responses one year after booster dose in RSV study
Negative
- None.
News Market Reaction – BVAXF
In the trading session that priced this news, BVAXF declined 1.96%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
This Patent was recently allowed in
DPX™ is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules. Its unique "no release" mechanism of action allows antigen presenting cells (APCs) to be attracted to the injection site, facilitating a robust and long-duration immune response.
The smallest dose of a currently approved vaccine is 0.1ml for Sanofi-Pasteur's Fluzone™ Intradermal Quadrivalent vaccine. Low dose volume delivery of DPX™ formulated B-cell epitope is designed to be delivered in single low dose volume of less than 100 µl that can package 5µL to 50 µL of of an antigen comprising a B-cell epitope.
An epitope is the part of an antigen that the host's immune system recognizes, eliciting the immune response to an invading pathogen. It specifically binds to the corresponding antigen receptor on the immune cell (such as a B-cell). Whereas T-cells protect people from getting infected by destroying cancerous and infected cells, B-cells produce antibodies to fight infection.
Potential applications of this technology include epitope-based vaccines for diseases such as chronic hepatitis-B, influenza, and Respiratory Syncytial Virus (RSV)---where BioVaxys' clinical study data is encouraging for product development.
In a prior randomized, observer-blinded, first-in-humans Phase 1 study of a novel synthetic RSV antigen based on the ectodomain of the small hydrophobic glycoprotein (SHe) of RSV subgroup A formulated with DPX ("DPX-RSV"), the data showed that more than nine months after the last vaccination, 15 of 16 participants (
BioVaxys President and Chief Operating Officer Kenneth Kovan stated "Issuance of this Patent by the USPTO expands the value of our IP and DPX platform, and puts the Company on strong footing for further development and partnering with companies developing epitope-based vaccines for diseases such as chronic hepatitis-B, influenza, and RSV, where we have such promising human study results."
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
+1 646 452 7054
Cautionary Statements Regarding Forward Looking Information
The CSE has neither approved nor disapproved the contents of this press release. The CSE does not accept responsibility for the adequacy or accuracy of this release. This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward- looking statements") within the meaning of applicable Canadian and
These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.
The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Logo - https://mma.prnewswire.com/media/1430981/4526799/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/biovaxys-announces-issuance-of-dpx-related-patent-from-the-us-patent-and-trademark-office-302203828.html
SOURCE BioVaxys Technology Corp.